Francesco De Rubertis - Co-Founder & Partner @ Medicxi

Start Free Trial

Pricing

Overview

Number of Portfolio Companies

Number of Current Board & Advisor Roles

Primary Job Title Co-Founder & Partner
Primary Organization
Medicxi

Location Geneva, Geneve, Switzerland
Regions Europe, Middle East, and Africa (EMEA)
Gender Male

Investor Type
obfuscated
obfuscation

X (Twitter) View on X

Francesco De Rubertis is the co-founder and Partner at Medicxi. He is the Board of Director at Ottimo Pharma. He attended the University of Geneva.

Personal Investments

Number of Investments

Francesco De Rubertis

invested in

Velada

obfuscation

. This investment -

Pre Seed Round - Velada

- was valued at

obfuscation

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Velada	—	Pre Seed Round - Velada	obfuscated obfuscation

Partner Investments

Number of Partner Investments

Announced Date	Organization Name	Investor Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	D3 Bio	Medicxi	—	Series B - D3 Bio	obfuscated obfuscation
obfuscated obfuscation	Ottimo Pharma	Medicxi	—	Series A - Ottimo Pharma	obfuscated obfuscation
obfuscated obfuscation	Ottimo Pharma	Medicxi	Yes	Seed Round - Ottimo Pharma	obfuscated obfuscation
obfuscated obfuscation	D3 Bio	Medicxi	Yes	Series A - D3 Bio	obfuscated obfuscation
obfuscated obfuscation	Alys Pharmaceuticals	Medicxi	Yes	Seed Round - Alys Pharmaceuticals	obfuscated obfuscation
obfuscated obfuscation	Aldena Therapeutics	Medicxi	Yes	Series A - Aldena Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Rivus Pharmaceuticals	Medicxi	—	Series B - Rivus Pharmaceuticals	obfuscated obfuscation
obfuscated obfuscation	Rivus Pharmaceuticals	Medicxi	Yes	Series A - Rivus Pharmaceuticals	obfuscated obfuscation
obfuscated obfuscation	SynOx Therapeutics	Medicxi	Yes	Series A - SynOx Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Versartis	Index Ventures	—	Series D - Versartis	obfuscated obfuscation

Jobs

Number of Current Jobs

Number of Past Jobs

Francesco De Rubertis

has

current jobs as

Director

Critical Pressure

and

Co-Founder & Partner

Medicxi

. Additionally,

Francesco De Rubertis

has had

past jobs including

Postdoctoral Scientist

Whitehead Institute for Biomedical Research

Critical Pressure Director
Medicxi Co-Founder & Partner

Organization Name	Title At Company	Start Date	End Date
Whitehead Institute for Biomedical Research	Postdoctoral Scientist	—	—
Index Ventures	Partner	1997	—

Board and Advisor Roles

Number of Current Board & Advisor Roles

Number of Past Board & Advisor Roles

Francesco De Rubertis

holds

board and advisor roles including

Board Member

Centessa Pharmaceuticals

Board Member

SynOx Therapeutics

, and

Board of Directors

Versartis

Centessa Pharmaceuticals Board MemberFeb 2021
SynOx Therapeutics Board MemberNov 19, 2020
Versartis Board of Directors
Rivus Pharmaceuticals Board Member
Aegerion Pharmaceuticals Investor
D3 Bio Board Member
Sequenta Board Member
Ottimo Pharma Board of Director
Addex Therapeutics Investor
Alys Pharmaceuticals Chairman of the Board

Organization Name	Title At Company	Start Date	End Date
ProFibrix	Investor	—	—
BioXell	Investor	—	—
GenSight Biologics	Investor	—	—
PanGenetics	Investor	—	—
ParAllele Bioscience	Investor	—	—
CellZome	Investor	—	—
Minerva Neuroscience	Investor	—	—
Genmab	Investor	—	—
Molecular Partners	Investor	—	—
Egalet	Investor	—	—

Related Hubs

Hub Name	CB Rank (Hub)
Female Founded Seed Stage Investors with Investments in Europe, Middle East, and Africa (EMEA)	19,586
Europe Seed Stage Investors	3,786
Female Founded Investors active in Europe, Middle East, and Africa (EMEA)	10,302
Seed Stage Investors with Investments in Europe	1,751
Female Founded Venture Capital Investors with Investments in Europe, Middle East, and Africa (EMEA)	20,896
Female Founded Early Stage Venture Investors with Investments in Europe, Middle East, and Africa (EM	23,651
Europe, Middle East, and Africa (EMEA) Female Founded Early Stage Venture Investors	30,252
Female Founded Venture Capital Investors	9,564
Female Founded Seed Stage Investors	12,577
Female Founded Early Stage Venture Investors with Investments in Europe	23,092